Clinical trials · Washington
Hematopoietic Stem Cell Transplant clinical trials in Washington
We’re tracking 28 recruiting hematopoietic stem cell transplant studies with a site in Washington — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Washington
- NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Edmonds, WashingtonAges 18 years+ - NCT06172296RecruitingPhase 3
Dinutuximab plus transplant for high-risk neuroblastoma
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Seattle, WashingtonAges Up to 30 years - NCT03980769RecruitingPhase 2
Stem cell transplant trial for non-cancer blood disorders
This Phase 2 study tests a specific chemotherapy combination (treosulfan, fludarabine, and thiotepa) before an unrelated or matched donor stem cell transplant. It may help people with certain non-cancer blood and immune disorders by trying to reset the immune system using donor stem cells.
Seattle, WashingtonAges Up to 50 years - NCT04829136Recruiting
Oral fiber supplement during donor stem cell transplant
This trial tests whether taking a fiber supplement by mouth during a donor stem cell transplant helps patients tolerate treatment and potentially recover better. It’s specifically for adults who are planning a donor (allogeneic) transplant for blood cancers.
Seattle, WashingtonAges 18 years+ - NCT07148947RecruitingPhase 2
Pacritinib with standard care before stem cell transplant for MPN
This trial tests adding pacritinib to standard hypomethylating agents (azacitidine or decitabine) before a stem cell transplant for people with myeloproliferative neoplasms (MPN) that have progressed to a more advanced phase.
Seattle, WashingtonAges 18 years+ - NCT06665100RecruitingPhase 2
Study of PUL-042 for RSV and Related Viruses in Immune-Compromised Patients
This trial tests an inhaled medicine (PUL-042) for people with blood cancers or who have had a stem cell transplant and now have a respiratory virus (parainfluenza, RSV, or human metapneumovirus). The goal is to see if the drug can help clear the virus and improve symptoms.
Seattle, WashingtonAges 18 years+ - NCT06529731RecruitingPhase 2
Interferon-Gamma and Donor Cells for Relapsed Leukemia After Transplant
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
Seattle, WashingtonAges 18 years+ - NCT03779854RecruitingPhase 2
Preventing graft-versus-host disease in kids after stem cell transplant
This trial tests whether removing certain immune cells (T cells) from the donor transplant can lower the risk of chronic graft-versus-host disease (long-term immune attack after transplant) in children and young adults with blood cancers. If you qualify, it may help improve transplant outcomes while tracking safety and side effects.
Seattle, WashingtonAges 6 months–26 years - NCT03126916RecruitingPhase 3
Testing added therapy for high-risk neuroblastoma in children
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Seattle, WashingtonAges 12 months–30 years - NCT03128034RecruitingPhase 1/Phase 2
Astatine-211 treatment before stem cell transplant for high-risk blood cancers
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
Seattle, WashingtonAges 18–75 - NCT03670966RecruitingPhase 1/Phase 2
Targeted iodine therapy, then donor transplant for hard leukemias
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
Seattle, WashingtonAges 18–75 - NCT03970096RecruitingPhase 2
Reduce graft-versus-host disease after stem cell transplant
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Seattle, WashingtonAges 1–60 - NCT04047628RecruitingPhase 3
MS patients with active relapsing disease comparing two treatment plans
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
Seattle, WashingtonAges 18–55 - NCT04098445Recruiting
Study of lung injury in children after stem cell transplant
This study follows children and teens who get a stem cell transplant to learn how lung problems develop over time. Your participation could help doctors better predict, prevent, and manage lung injury after transplant.
Seattle, WashingtonAges Up to 24 years - NCT04195633RecruitingPhase 2
Haploidentical donor stem cell transplant to treat blood cancers
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
Seattle, WashingtonAges 6 months+ - NCT04293562RecruitingPhase 3
Testing targeted drugs plus chemo for newly diagnosed AML
This study compares standard chemotherapy to chemotherapy plus CPX-351 and/or gilteritinib in children and young adults newly diagnosed with AML. It aims to see whether adding these targeted treatments improves outcomes, especially for certain gene changes like FLT3.
Seattle, WashingtonAges Up to 21 years - NCT04375631RecruitingPhase 1
Study of chemo plus donor stem cell transplant for blood cancers
This Phase 1 trial tests a specific chemotherapy plan followed by a reduced-intensity donor stem cell transplant for people with relapsed or treatment-resistant acute myeloid leukemia (AML), certain myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It may help by using donor stem cells to rebuild the bone marrow after intensive cancer treatment, in people who are not responding well to standard therapies.
Seattle, WashingtonAges 18 years+ - NCT05855083RecruitingPhase 2
Narsoplimab for high-risk TMA after bone marrow transplant
This trial studies the medicine narsoplimab in children who develop a serious complication called HSCT-TMA after a bone marrow transplant. It aims to improve safety and effectiveness for high-risk cases where the condition is ongoing or causing organ problems.
Seattle, WashingtonAges 4 weeks–17 years - NCT06462365RecruitingPhase 1
Preventing GvHD after stem cell transplant for blood cancers
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
Seattle, WashingtonAges 18 years+ - NCT06724237RecruitingPhase 3
High-dose chemo and stem cell transplant for T-cell lymphoma patients in remission
This trial tests whether high-dose chemotherapy followed by a stem cell transplant using your own cells can help people with certain types of peripheral T-cell lymphoma live longer. You would qualify if you have already finished your first round of chemotherapy and are in complete remission.
Aberdeen, WashingtonAges 18–75 - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Seattle, WashingtonAges 18–66 - NCT06928662RecruitingPhase 1/Phase 2
Chemo, radiation, and donor stem cell transplant for high-risk blood cancers
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
Seattle, WashingtonAges 18 years+ - NCT06938867RecruitingPhase 1/Phase 2
Study of SNIPR001 for resistant gut bacteria before stem cell transplant
This study tests an experimental oral medicine called SNIPR001. It is designed to reduce resistant E. coli bacteria in the gut before your stem cell transplant, possibly lowering the risk of infection.
Seattle, WashingtonAges 18 years+ - NCT07046078RecruitingPhase 2
Chemo, radiation, and donor transplant for older adults with high-risk AML
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
Seattle, WashingtonAges 18 years+
Hematopoietic Stem Cell Transplant trials by city in Washington
Where these studies are running in Washington
Institutions with a site for the recruiting hematopoietic stem cell transplant studies listed above.
- Fred Hutchinson Cancer Center · 18 studies
- Seattle Children's Hospital · 4 studies
- Mary Bridge Children's Hospital and Health Center · 3 studies
- Providence Sacred Heart Medical Center and Children's Hospital · 3 studies
- Madigan Army Medical Center · 2 studies
- Swedish Cancer Institute-Edmonds · 2 studies
- Swedish Cancer Institute-Issaquah · 2 studies
- Swedish Medical Center · 2 studies
What taking part in a hematopoietic stem cell transplant study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Hematopoietic Stem Cell Transplant trials in other states
Common questions
- Are there hematopoietic stem cell transplant clinical trials in Washington?
- Yes. We're currently tracking 28 recruiting hematopoietic stem cell transplant studies with a site in Washington, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a hematopoietic stem cell transplant study in Washington?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington to take part?
- Not necessarily. These studies have a site in Washington, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a hematopoietic stem cell transplant trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New hematopoietic stem cell transplant studies open in Washington regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.